Objectives: Routine application of positron emission tomography/ computed tomography (PET/CT) for pancreatic cancer staging remains a controversial approach. The purpose of this study was to reassess the clinical impact of PET/CT for the detection of distant metastasis of pancreatic cancer.
T he incidence of pancreatic cancer has risen steadily over the past 4 decades and now ranks fifth among the leading causes of cancer fatalities in South Korea. 1 Despite advances in diagnostic and therapeutic medical technologies, pancreatic cancer still has a dismal prognosis with a 5-year survival rate of less than 5%. 2 Complete surgical resection is the only potentially curative treatment, yet less than 20% of all patients are considered candidates for curative resection at the time of diagnosis, 3 and the 5-year survival rate is only 22.5%, even after patients undergo surgery with a curative intent and adjuvant chemotherapy. 4 Given the high morbidity and mortality of surgery for pancreatic cancers, 5 the preoperative selection of patients who are suitable for surgery is crucial. Detection of distant metastasis is one of the most important factors when deciding whether an operation should be performed for pancreatic cancer. Despite the advances of modern imaging modalities, adequately assessing the resectability of pancreatic cancer is still challenging. Positron emission tomography (PET) is an evolving technology that has been developed in the past 15 years to allow functional imaging. Using 18 F-2-deoxy-D-glucose (FDG), which is a glucose analog, the enhanced metabolism of glucose by malignant cells causes uptake of the radiotracer. More recently, the functional information provided by PET has been fused with the anatomical detail of computed tomography (CT), and this has become the current standard in functional imaging. 6 Within a few years, PET/CT has rapidly replaced stand-alone PET. 7 It has emerged as a promising diagnostic staging modality for malignancies in various organs such as colorectal cancer, lung cancer, and lymphoma.
8Y10 Unlike these cancers, for which the clear efficacy of PET/CT has been demonstrated for the detection of metastasis, impacting therapeutic management, the routine application of PET/CT for pancreatic cancer staging still remains controversial. Only a few studies have evaluated the efficacy of PET/CT for detecting metastasis.
The aim of this study was to reassess the role of PET/CT for detecting hidden metastasis and its impact on the therapeutic management of pancreatic cancer after a conventional staging workup that included multiYdetector-row CT (MDCT).
MATERIALS AND METHODS

Patients
We retrospectively investigated the clinical data of 125 patients who were diagnosed with pancreatic cancer and underwent integrated PET/CT at Samsung Medical Center, Seoul, South Korea between January 2006 and June 2009. All the pancreatic cancers in this study were proven histologically. Patients with other pancreatic malignancies such as neuroendocrine tumors or intraductal papillary mucinous neoplasms were excluded from the study. Patients with a poor general condition (performance status 3 or 4, according to the Eastern Cooperative Group scale) or with severe comorbidities that precluded them from undergoing surgery were also excluded on the basis of their medical records. The patients' clinical information including age, sex, comorbidities, chief complaints, initial serum carbohydrate antigen (CA) 19-9 level and tumor locations were reviewed.
Conventional Staging Workup
Surgical resectability was assessed by multidisciplinary discussions based on a conventional staging workup, including MDCT, magnetic resonance imaging (MRI), chest x-ray, and endoscopic ultrasonography (EUS). All of these imaging modalities were performed on the selected patients. Positron emission tomography/computed tomography was performed within a 1-month interval in addition to the other conventional staging workup. All the patients who underwent laparotomy were reassessed postoperatively for their tumor stages.
Pancreatic cancers with distant metastasis and locally advanced disease were considered unresectable. Common locally advanced diseases included invasion of major arteries, such as the celiac trunk, hepatic artery, and superior mesenteric artery (SMA), and long-segment involvement of the portal vein and superior mesenteric vein.
The PET/CT Protocol
The 18 F-FDG PET study was performed on a dedicated PET scanner (Advance; GE Healthcare, Milwaukee, Wis). All the patients were asked to fast for at least 6 hours before the examination. The blood glucose level of each patient was determined before he/she underwent PET/CT scanning. Scanning of patients with diabetes mellitus was not performed until the blood glucose level was less than 110 mg/dL.
The whole-body CT scanning was performed using a continuous spiral technique on an 8-slice helical CT with a gantry rotation speed of 0.8 second. The CT scan data were collected with 40 to 80 mAs as adjusted to the patients' body weight, 140 keV, a 5-mm section width, and a table feed of 5 mm per rotation. No contrast material was administered. After the CT scan, an emission scan was performed from the thigh to the head for 5 minutes per frame and 45 minutes after the intravenous injection of 370 MBq FDG. The attenuation-corrected PET images using the CT data were reconstructed using an ordered subsets expectation maximization algorithm (28 subsets, 2 iterations). Commercial software (eNTEGRA; Elgems, Haifa, Israel) was used to accurately coregister the separate CT and PET scan data. The standardized uptake values (SUVs) were acquired using the attenuation-corrected images, the amount of the injected FDG, the body weight of each patient, and the cross-calibration factors between PET and the dose calibrator. Glucose uptake was determined by the SUV, with an SUV of more than 2.5 considered indicative of malignancy.
The MDCT Protocol
Computed tomographic scanning was performed with an MDCT scanner (LightSpeed Ultra; GE Healthcare). A total dose of 2 mg/kg of a nonionic contrast agent (iopromide, Ultravist; Schering, Berlin, Germany) was administrated intravenously via an 18-gauge angiographic catheter at a rate of 4 mL/s. A total of 120 mL of nonionic contrast material (Ultravist 300, 300 mg/mL iopromide; Schering) was administered intravenously with an automatic injector at a rate of 3 to 4 mL/s. The arterial phase (2.5-mm slice thickness) was obtained at 45 seconds, and the portal phase (5-mm slice thickness) was obtained at 70 seconds after initiation of the contrast material injection, respectively. The CT scans of patients referred to our institution from affiliated hospitals underwent radiological evaluation, and if they did not comply with our institutional standards, the CT was repeated.
Diagnostic Accuracy and the Impact of PET/CT on Patient Management
The diagnostic accuracy for assessing the cancer stage was determined by calculating the correlation between the intraoperative findings and the pathologic reports, or the serial followups for a minimum of 6 months. If there was significant evidence of progression on serial imaging, the lesion was considered to be malignant. The clinical outcome was assessed by reviewing the medical record. To evaluate the clinical efficacy of PET/CT on the management plan, the post-PET/CT management plan was compared with the pre-PET/CT management plan. The sensitivities of both the conventional staging workup and the combination of the conventional staging with PET/CTwere compared to assess the efficacy of PET/CT for the detection of metastasis.
We performed a direct cost-benefit comparison as a consequence of the additional application of PET/CT for patients whose lesions were determined to be resectable after standard staging workup. The overall costs of PET/CT for patients with resectable lesions were calculated, derived from our accounting department reflecting the real cost. Costs for pathologic confirmation of metastatic lesions were added to the cost of PET/ CT. The benefit with the use of PET/CT was assumed as the saved cost by avoiding unnecessary surgery. Costs for pancreatic surgery were based on average charged costs of 9 consecutive patients over the previous month before analysis, including the mean daily charged cost for the postoperative days. Cost are expressed in US dollars (US $), using the exchange rate as of June 2010: US $1 = 1196 Korean won.
Statistical Analysis
The sensitivity of PET/CT for the detection of pancreatic cancer metastasis was calculated using the pathology results and clinical outcome. The McNemar test was performed to compare the sensitivity of detecting metastasis with PET/CT combined with conventional staging versus conventional staging only. Statistical analyses were performed using SPSS software (version 18.0; SPSS Inc, Chicago, Ill). P G 0.05 was considered to be statistically significant.
RESULTS
Clinical Profiles of all the Pancreatic Cancer Patients
One hundred twenty-five patients who had a pancreatic cancer and underwent a PET/CT scan were analyzed. All the patients were diagnosed pathologically. Seventy-three patients were confirmed to have pancreatic ductal adenocarcinoma after surgery, and 52 were confirmed after tissue biopsies. All the patients' baseline characteristics are shown in Table 1 . Figure 1 shows the clinical profiles and therapeutic decisions for all of the 125 consecutive patients.
Conventional Preoperative Staging for the Detection of Distant Metastasis
A conventional staging workup was performed for all patients, and they underwent MDCT scanning and chest x-ray. Liver or pancreas MRI and EUS were performed for selected patients; 28% of the patients (n = 35) underwent MRI, and 38% of the patients (n = 48) underwent EUS.
After conventional staging, we determined that 76 patients (60.8%) had resectable lesions, and 48 patients had unresectable lesions. The reasons for unresectability after conventional staging included distant metastasis (32 patients) and locally advanced disease (16 patients). Patients with locally advanced disease and distant metastasis were regarded as having distant metastasis. The preoperative stages of the patients with resectable lesions by the conventional staging were as follows: 10.7% (n = 8) in stage IA, 22.7% (n = 17) in stage IB, 37.3% (n = 28) in stage IIA, 25.3% (n = 19) in stage IIB, and 1.3% (n = 1) in stage III. The characteristics of patients who underwent surgery are shown in Table 2 .
The metastatic lesions detected by conventional staging were mainly identified by MDCT, MRI, and chest x-ray or chest CT. Among the 32 patients with distant metastasis, 27 patients underwent biopsy confirmation for the metastatic lesions or positive malignant cells by fine-needle aspiration (FNA) (18 patients with liver, 4 with lung, 2 with left supraclavicular lymph node for palpable lymphadenopathy, 1 with colon, and 2 with peritoneum metastases). In the remaining 5 patients, 2 patients with peritoneal carcinomatosis, 2 with liver and lung metastasis, and 1 with liver metastasis were clinically confirmed. All of them had locally advanced, unresectable disease on initial MDCT and underwent EUS-guided FNA on the primary pancreatic cancer lesion, which was confirmed as pancreatic ductal adenocarcinoma. Among them, the metastatic lesions of 3 patients were confirmed by serial CT and clinical follow-up with expanding lesions and progressions, whereas 2 patients were lost to follow-up.
One patient with an advanced T stage underwent explorative laparotomy, and the patient was finally confirmed as having liver metastasis with frozen-section biopsy during the operation.
PET/CT for the Evaluation of Distant Metastasis
All of the 125 patients included in the study underwent PET/CT, which detected additional distant metastasis in 3 patients not identified by the conventional staging protocol. One of these patients already had locally advanced disease, such as invasion to the SMA. The other 2 patients had resectable tumors initially based on the conventional staging protocol; one of them was at stage IIA, and the other was at stage IIB. After PET/CT, the patient at stage IIA showed increased FDG uptake in the proximal duodenum, which was positive for pancreatic adenocarcinoma on duodenal biopsy. Moreover, the PET/CT result also showed 2 soft tissue lesions with increased FDG uptake in the left peritoneum and surrounding the SMA area, indicative of peritoneal dissemination (Fig. 2 ). These were clinically confirmed as significant progression on serial CT follow-up. The PET/CT result of the other patient showed increased uptake in the left supraclavicular lymph node (Fig. 3) , which was proven to be metastasis, confirmed by FNA. Their clinical characteristics are shown in Table 3 .
Among the 74 patients with resectable lesions who underwent laparotomy, 8 patients were determined to have distant metastasis during the operation: liver metastasis in 5 patients, peritoneal seeding in 2 patients, and para-aortic lymph node metastasis in 1 patient. All of the metastatic lesions were confirmed by frozen-section biopsy, and their clinical characteristics are shown in Table 4 . Two of these 8 patients were suspected of having liver metastasis on the initial MDCT, but they underwent surgery because of negative findings on liver MRI and PET/CT. A total of 44 patients were finally confirmed to have metastatic disease: 32 patients after conventional staging, 1 patient after explorative laparotomy, 3 patients after PET/CT, and 8 patients at the time of surgery. Of these patients, PET/CT correctly detected metastatic disease in 32 patients at a sensitivity of 72.7%.
Impact of PET/CT on the Clinical Management
As described above, PET/CT detected 3 additional metastasis incidents that were not detected with conventional staging. One of these patients already exhibited locally advanced disease, and the therapeutic management plan was not influenced by thePET/CT result used to detect the metastasis in the left parotid gland. Among the 76 patients who were deemed to undergo curative surgery after conventional staging, PET/CT diagnosed distant metastasis in 2 patients (2.6%), after which they did not undergo unnecessary surgical treatment.
The sensitivity of conventional staging with the combination of conventional staging and PET/CT was compared for the detection of occult metastasis, and no statistically significant difference was observed (72.7% vs 79.5%, respectively; P = 0.25, McNemar test) ( Table 5 ). As the MDCT plays a key role in initial diagnosis and assessing the tumor stage of pancreatic cancer, we evaluated the sensitivity of MDCT for the detection of distant metastasis. MultiYdetector-row CT properly detected distant metastasis in 33 of 44 patients at a sensitivity of 75%, which was not significantly different to that of PET/CT (75% vs 72.7%, respectively, P = 1.000, McNemar test).
DISCUSSION
There has been controversy as to whether PET/CT is essential for the preoperative staging of pancreatic cancer. This study was undertaken to define the role of PET/CT for the initial staging of pancreatic cancer and to determine what percentage of patients had their clinical management altered based on the PET/CT results. Our study showed that after conventional staging that included MDCT, the PET/CT result changed the management plan by detecting additional metastasis in only 2 patients (2.6%) of the 76 patients with resectable lesions, and they did not undergo unnecessary surgical exploration.
In a previous study on 82 patients with suspected pancreatic cancer, PET/CT changed the management for 11% of the patients with resectable lesions. 11 Similarly, Heinrich et al 12 evaluated PET/CT in 59 patients with both benign and malignant pancreatic masses. They reported that PET/CT eventually altered the management plan for 16% of the patients. 12 In another study by Kauhanen et al, 13 PET/CT showed a higher sensitivity of 88% for detecting metastasis, as compared with a sensitivity of 38% for MDCT and MRI. It was concluded that PET/CT should be considered in routine staging of patients with potentially resectable pancreatic lesions. However, the aforementioned studies were limited by relatively heterogenous populations and small sample sizes of 37 patients 12 and 17 patients 13 with pancreatic ductal adenocarcinoma.
The introduction of multiYdetector-row helical CT scanners has markedly improved the speed and quality of cross-sectional imaging, 14Y16 and this has become the first diagnostic modality to evaluate patients suspected of having pancreatic disease. It has played a valuable role in assessing the resectability of pancreatic cancer with the reduction of the voxel size, rapid image reconstruction, and high spatial resolution, thus being able to detect vascular invasion, regional lymph node metastasis, and distant metastasis. The ability to obtain thinner slices can improve the detection of small peritoneal and hepatic metastases, which is difficult to detect by PET/CT imaging. In the present study, MDCT had a sensitivity of 75% for detecting metastasis, which showed no significant differences with that of PET/ CT or a combination of conventional imaging and PET/CT. Interestingly, 2 of the 8 patients who underwent surgery but were finally determined to have distant metastasis were suspected of having liver metastasis on the initial MDCT, yet had negative findings on the liver MRI and PET/CT. This is in concordance with previous reports that the MDCT is a very accurate imaging modality for assessing liver metastasis. 17, 18 The present study demonstrated that PET/CT diagnosed distant metastasis in 32 (72.7%) of 44 patients with metastatic lesions. This sensitivity was similar to that of previous reports. This also served as indirect evidence that the PET/CT scans were done correctly after MDCT. Combined with conventional staging, PET/CT provided more information on the pancreatic cancer patients in our study, which resulted in lower efficacy of PET/CT than that of previous studies. For pancreatic cancer patients who have undergone resection, most recurrences occurred in the abdomen and largely in the liver (47%) and peritoneum (13%) as a distant metastasis rather than a locoregional site. 19 This pattern of recurrence supports the need to perform As demonstrated in our study, a negative PET/CT scan may not be sufficient to reliably exclude malignancy. There were 10.8% (8 of 74 patients) false-negative results of PET/CT for the pancreatic cancer patients in which occult metastases were discovered during the operation. More than half (5/8) of the metastases were in the liver, and 2 of them were in the peritoneum. It is a well-known fact that small tumors of less than 1 cm are difficult to detect because of the low spatial resolution of PET scanners. 20 Nishiyama et al 21 reported a sensitivity of 81.8% for detecting metastatic disease by FDG-PET, but further analysis of this study reveals an important weakness of FDG-PET. Whereas 88% of the metastatic liver lesions larger than 1 cm were positive on FDG-PET, only 50% of the lesions smaller than 1 cm were detected. The activity in small lesions is underestimated because of the partial volume effect. In addition, the liver has high physiologic FDG uptake in the background, and this may obscure metastatic lesions and cause false-negative PET results. These findings indicate that the sensitivity of PET is limited for the detection of subcentimeter liver metastases.
20Y22
Contrast-enhanced PET/CT was designed to combine the benefits of both MDCT and PET. The performance of contrastenhanced PET/CT for pancreatic cancer patients was evaluated in 2 studies, 23, 24 but both these studies were limited because of a small number of patients as well as the observation that they failed to show superiority over nonenhanced PET/CT in the detection of metastasis. The benefit from a clinical application of contrast-enhanced PET/CT demands further studies.
Because PET/CT is an expensive diagnostic tool, assessing its cost-effectiveness is always challenging. In the present study, the cost-benefit as a consequence of the additional application of PET/CT to the conventional staging procedure was assessed. The cost for PET/CT per patient amounted to US $607.6 at our hospital, whereas the total cost of PET/CT for all 76 patients with resectable lesions amounted to US $46,177.6. There were 2 patients whose lesions were deemed to be resectable by standard staging workup but were determined to have metastatic disease by PET/CT. One of them was positive for metastatic pancreatic adenocarcinoma on the duodenal biopsy, which was US $95.8 including charges for the esophagogastroduodenoscopy and histopathologic confirmation. The other was found to have left supraclavicular lymph node metastasis confirmed by FNA, which costs US $219.7, including the intervention fee and cytologic processing. Therefore, the overall costs for PET/CT including these interventions and pathologic examination amounted to US $46,493.1. On the other hand, the mean costs of pancreatic surgery for pancreatic cancer per patient at our hospital were US $3347. The median length of postoperative hospital days was 11 days, with the mean charge for postoperative period costing US $4391.2. Therefore, the total cost for pancreatic resection amounted to US $7738.2. There were only 2 patients who benefited from PET/CT. Therefore, US $15,476 was the cost saved from unnecessary surgery, whereas the cost of PET/CT for the 76 patients who planned to undergo surgery was approximately US $46,493.1. From an economic perspective, the routine application PET/CT in preoperative staging is clearly not cost-effective.
Therefore, how can we select patients who would benefit from PET/CT after conventional staging workup? The utility of a tumor marker has been suggested for the prediction of resectability to avoid unnecessary laparotomy. Carbohydrate antigen 19-9 is the most widely studied tumor marker that has been evaluated for diagnosis and prognosis in pancreatic cancer patients. It has been suggested that serum perioperative CA-19-9 levels may correlate with the tumor burden, disease spread, and metastasis. 25Y27 In a recent study by Kim et al, 28 a high serum CA-19-9 level predicted unresectability with 88.6% accuracy, even with localized pancreatic cancer on preoperative CT. They recommended that a pancreatic cancer patient for whom preoperative CT demonstrates only a localized tumor but whose tumor marker shows higher than cutoff level needs a further staging modality such as PET/CT or diagnostic laparoscopy. That is partially concordant with our data, because the 2 patients who benefited from PET/CT had excessively high serum CA-19-9 levels, 6590.7 and 2988.4 U/mL (Table 3) . However, CA-19-9 levels neither reliably predict the resectability nor exclude the presence of metastasis in our study. Among the 44 patients who were finally confirmed with metastasis, 20 patients showed serum CA-19-9 levels of less than 100 U/mL. Moreover, 3 of 8 patients who were determined to have distant metastasis during the operation had normal serum CA-19-9 levels (Table 4) . Therefore, it may be reasonable to assume that CA-19-9 can be used only as an adjunct indicator of unresectability when serum levels are excessively elevated preoperatively.
Staging laparoscopy has also emerged as a promising method for patients with imaging occult disease to avoid unnecessary laparotomy. However, it has been argued that in patients with potentially resectable tumors who undergo preoperative highquality MDCT, the yield of laparoscopy is only 3% to 14%.
29Y31
Potentially patients with resectable lesions who undergo laparoscopy following high-quality preoperative imaging will have negative findings, therefore not affecting the management plan of the majority of patients examined. Only a small percentage of patients would benefit from laparoscopy, which means that the routine use of staging laparoscopy may not be easily justified. The search for ways to improve staging of pancreatic cancer continues to be an active area of research; there is still no absolute 1-step modality for predicting resectability.
The present study is one of the largest reports evaluating the value of PET/CT for detecting distant metastasis of pancreatic cancer. The study population was homogenous as only histologically confirmed pancreatic cancer patients were included, although the study was limited by the retrospective study design.
In conclusion, PET/CT is not obligatory for the preoperative staging of pancreatic cancer, although PET/CT has been reported to have potential advantages for detecting pancreatic cancer because it is a functional imaging that reflects a high rate of glucose metabolism. However, it seemed not to surpass MDCT for properly staging pancreatic cancer. Pancreatic cancer has a large desmoplastic area and low glucose metabolism. This fact, along with the greater availability of MDCT, favors the selective use of PET/CT. Given the low sensitivity for detection of the metastasis and poor cost-effectiveness of PET/ CT, PET/CT plays only a limited role for the evaluation of metastatic disease in pancreatic cancer. Therefore, PET/CT should be used as adjuvant to the current standard staging and imaging methods.
